Court stays out of Planned Parenthood funding case
The Supreme Court will not disturb a lower court ruling that blocks Indiana's effort to strip Medicaid funds from Planned Parenthood because the organization performs abortions.
Health Care & Life Sciences
Articles
A dose of reality about the business of health care
Welcome to The Dose, a blog about the business of health care. As your host, J.K. Wall, I'll be writing about the most interesting new developments I see at hospitals, doctors, insurers, employers, patients, drugmakers, device companies and medical researchers around Indianapolis and around the country.
Think again: Why Obama’s disclosure of hospital charges won’t help you
In the first post on my new blog, The Dose, I explain why the recently released Medicare charge data are meaningless for everyone but uninsured patients.
WellPoint among 13 picked to join California exchange
California residents who choose to buy health insurance through the state exchange being created by the Affordable Care Act may end up paying higher premiums.
New WellPoint CEO Joe Swedish thrives on complexity
Joe Swedish, a career hospital executive, is now two months into his job at the helm of Indianapolis-based WellPoint, the nation’s second-largest health insurer. In his first interview since starting work, Swedish indicated he’s taking his time to learn the people and the culture of the vast organization he now leads.
Forecast: Cash to reign in health care
With premiums for health insurance likely to head north next year as President Obama’s health care reform law fully takes effect, both individuals and employers will pay for more health care out of their own funds and buy less insurance.
Lilly study: 1 in 5 Alzheimer’s patients misdiagnosed
The study results, which will be released Monday afternoon, are part of Indianapolis-based Lilly’s campaign to get Medicare to pay for use of its brain imaging agent Amyvid.
Work stops on Greenwood pharmaceutical plant
Greenwood officials three years ago approved $8.4 million of incentives for the Elona Biotechnologies project, including the construction loan.
Canada’s Supreme Court won’t hear Lilly appeal on Zyprexa
Eli Lilly claims recent decisions by Canadian courts invalidating 17 drug patents have made the country an outlier among major developed countries.
Mobile health apps could cut into state companies’ market share
The future of Indiana’s sprawling health care and life sciences industry might be threatened by an unlikely source: smartphone apps.
Surprise director departures boost WellPoint shares
Outside observers cast the departures of Lenox Baker, Sheila Burke and Susan Bayh as a positive that will allow new CEO Joseph Swedish to recast the board.
Lechleiter’s surgery to repair heart goes as planned
Eli Lilly and Co. CEO John Lechleiter underwent a scheduled surgery Monday for a heart defect, and the repair to the aorta is functioning as intended, the Indianapolis-based drugmaker said.
Three WellPoint directors step down, cite personal reasons
Lenox Baker, Sheila Burke and Susan Bayh resigned from the board effective immediately, Indianapolis-based WellPoint said Monday in a regulatory filing.
Michigan doctor named dean of IU School of Medicine
Dr. Jay Hess was picked to become the 10th dean in the school of medicine’s 110-year history and the first dean in the past five to come from outside IU.
Indiana device makers absorbing Obamacare excise tax
The state’s medical-device companies are finding that they cannot pass on the new medical-device tax created by Obamacare to their hospital customers, causing them to continue to make cuts and to look to foreign markets for more profitable growth.
Study rebuts hospitals’ argument on Medicare, rising costs
Rather than raising prices on private health insurers to make up for inadequate payments from the government, hospitals across the country have been raising prices just because they can, according to a new study.
PANEL: Life sciences will see radically different future
IBJ convened a panel of experts at its Life Sciences Power Breakfast on May 10 to talk about the industry issues of venture capital, digital health innovations and research university entrepreneurship.
Panel members included Kristin Eilenberg, CEO, Lodestone Logic, Infuse Accelerator; Philip S. Low, Purdue University professor of chemistry, founder and chief science officer at Endocyte Inc. and On Target Laboratories LLC; R. Matthew Neff, president, CHV Capital Inc.; Brian Stemme, project director; BioCrossroads; Brian S. Williams, director, Global Healthcare Strategy, PricewaterhouseCoopers International Ltd.; and Raul Zaveleta, CEO, Indigo BioSystems Inc.
The following is an unedited transcript of the discussion.